Please login to the form below

Not currently logged in


This page shows the latest pricing news and features for those working in and with pharma, biotech and healthcare.

NICE appraisal fees to be introduced despite opposition

NICE appraisal fees to be introduced despite opposition

The charges have been confirmed just days after a new 5 year UK pricing deal was finalised between the Department of Health and Social Care (DHSC) and the industry representative body

Latest news

More from news
Approximately 87 fully matching, plus 761 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 16 fully matching, plus 145 partially matching documents found.

Latest appointments

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    She will also oversee marketing, pricing, forecasting and analytics. Brian Hoffmann, president of Hikma’s generics division, said:  “I am looking forward to working closely with Kristy and her team to

  • Weekly comms appointments Weekly comms appointments

    Pyati’s new domain will see him grow and expand the group’s scientific and medical communications practice and integrating it with the firm’s analytics, digital and value, pricing and

  • Claes Buxfeldt joins NDA Claes Buxfeldt joins NDA

    He has represented the payer voice in development programmes including the development of payer evidence strategies, pricing, market access strategy, economic models and clinical programme input.

  • Mereo BioPharma appoints head of patient access and commercial planning Mereo BioPharma appoints head of patient access and commercial planning

    In this role, Hughes-Wilson was responsible for Sobi’s commercialisation approach and led pricing, reimbursement and access teams for the group’s rare disease product portfolio.

  • W2O bolsters its commercialisation offering W2O bolsters its commercialisation offering

    Rita Glaze joins the firm as leader of value, pricing and market access practice. ... Glaze has 25 years’ experience in the biopharmaceutical and life science sector with expertise in marketing, managed markets, pricing strategy and communications.

More from appointments
Approximately 2 fully matching, plus 28 partially matching documents found.

Latest from PMHub

  • PR-it

    PR-it combines the power of a global community of high-calibre, seasoned public relations, digital and creative experts with a proprietary data-driven pricing model.

  • PRMA Consulting Ltd

    PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international pharmaceutical and biotechnology companies today. ... Our tailored services include strategic market

  • Patients’willingness to pay

    Considerations when developing an appropriate pricing strategy in self-pay markets. When launching a new product, it’s critical that pharma chooses the right pricing strategy to achieve the optimal balance ... In emerging markets, pricing is made more

  • Combination therapies in oncology: The benefits of integrated insights

    Key Learning Objectives:. Delegates will:. Learn about the major themes, challenges and opportunities for marketing an oncology therapy in combination, including clinical trial design, pricing, sequencing and product attributes, amongst others.

  • How integrated insights supported a biologic launch strategy across multiple indications

    Our client is launching a new biologic in dermatology across indications and needed to understand the market, including the patient pool, treatment landscape, potential uptake and pricing opportunity for their new

More from PMHub
Approximately 7 fully matching, plus 48 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...